Show simple item record

dc.contributor.authorGriffiths, Owen
dc.contributor.authorLandon, John
dc.contributor.authorCoxon, Ruth
dc.contributor.authorMorris, Keith
dc.contributor.authorJames, Philip
dc.contributor.authorAdams, Rachel
dc.date.accessioned2020-06-11T09:41:53Z
dc.date.available2020-06-11T09:41:53Z
dc.date.issued2020-01-10
dc.identifier.citationGriffiths, O.R., Landon, J., Coxon, R.E., Morris, K., James, P. and Adams, R. (2020) Inflammatory bowel disease and targeted oral anti-TNFα therapy. In: R. Donev (ed.) Advances in Protein Chemistry and Structural Biology, vol. 119, pp. 157-198.en_US
dc.identifier.urihttp://hdl.handle.net/10369/11065
dc.descriptionBook chapter in Donev (2020) Advances in Protein Chemistry and Structural Biology, vol. 119.en_US
dc.description.abstractAntibodies have provided invaluable treatment options for many diseases, with immunotherapy revolutionising the treatment of several inflammatory disorders including inflammatory bowel disease (IBD). Accumulating evidence suggests that IBD results from an inappropriate response to intestinal microbes and environmental factors in genetically susceptible individuals, with overactivity of the pro-inflammatory pathways. On a pathophysiological level, IBD is a complex disease with intestinal fibrosis, stenosis and an increased incidence of cancer observed in those whose disease is inadequately controlled over time. Regulating the actions of the pro-inflammatory cytokine human tumor necrosis factor-alpha (hTNFα) through the use of anti-TNFα monoclonal antibodies (e.g. infliximab, certolizumab, adalimumab and golimumab) has proven an effective intervention for IBD with their increased use a testament of their effectiveness. These agents are administered systemically thereby causing their distribution throughout the body in a condition that is localised to the gastrointestinal (GI) tract. Immunogenicity, the induction of anti-drug antibodies (ADAs), serum sickness and other undesirable side effects limit their use, whilst up to 50% of patients do not respond to initial therapy. Diseases confined to the GI tract are ideal for targeting by oral therapy which mitigates side effects and allows for lower doses to be administered. Several oral anti-TNFα agents have been investigated with success but are not yet in general clinical use. This partially reflects the fact that the oral administration of antibodies has many barriers including the harsh environment of the GI tract and the presence of enzymes including pepsin, trypsin and chymotrypsin in the intestine which provide significant challenges to targeted oral therapy.en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.titleChapter Five - Inflammatory bowel disease and targeted oral anti-TNF therapyen_US
dc.typeBook chapteren_US
dc.identifier.doihttps://doi.org/10.1016/bs.apcsb.2019.08.009
rioxxterms.versionNAen_US
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden_US
rioxxterms.licenseref.startdate2020-06-11


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record